Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 21, 2026

Social Security's 2027 Cost-of-Living Adjustment (COLA) May Be Among the Largest in 25 Years -- but There's a Catch

View original at nasdaq.com
Social Security's 2027 Cost-of-Living Adjustment (COLA) May Be Among the Largest in 25 Years -- but There's a Catch Key Points Social Security's annual COLA reveal in October is arguably the most anticipated announcement of the year for program recipients…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • There's a real possibility of the 2027 COLA being among the largest over the last quarter century

    60% confidence
  • Social Security benefits will increase by 2.8% in 2027

    60% confidence
  • Medicare's Part B premium is rising at a significantly faster pace than Social Security's annual COLA more often than not

    60% confidence
  • A larger-than-expected COLA in 2027 won't change the fact that a Social Security dollar simply isn't what it used to be

    60% confidence
  • Gas prices in the US have moved up to $3.79/gallon, their highest level since September 2023. The 30% spike over the last month ($2.92/gallon to $3.79/gallon) is the biggest we've seen in the past 30 years.

    60% confidence
  • The purchasing power of Social Security income declined 36% from the start of the 21st century to February 2023

    60% confidence
  • The purchasing power of Social Security income dropped 20% from 2010 to 2024

    60% confidence
  • Social Security benefits will rise by 1.7% in 2027

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Social Security's 2027 Cost-of-Living Adjustment (COLA) May Be Among the Largest in 25 Years -- but There's a Catch — Source | Via News | Via News